Institute of Cardiovascular and Metabolic Diseases (I2MC - UMR1048)

The new Institute of Cardiovascular and Metabolic Diseases (I2MC) was created in Toulouse on January 1, 2011 by Inserm and Paul Sabatier University.

l4

More than 280 people (scientists, physicians, engineers, technicians, students, postdocs and administrators) are working at I2MC

The research activity focuses on metabolic, cardiovascular and renal diseases. The main feature of I2MC is the gathering of basic scientists together with clinicians working on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (thrombosis, atherosclerosis, cardiac and renal failure).

schema accueil v5

I2MC is composed of 14 research teams. The teams share a similar "research philosophy" consisting in multidisciplinary approaches from basic science to clinical trials. In terms of basic research, the laboratories have a large expertise in membrane and intracellular receptors, cell signaling, metabolic pathways, cell/cell interactions and the mechanisms of tissue remodeling. To establish the pathophysiological relevance of the results obtained in basic research, I2MC teams have created original animal models and phenotyping techniques that have gained national recognition and are one of the highlights of the Institute. Translation to the clinic is greatly facilitated by the location within the Rangueil site of Toulouse University Hospitals. Notably, clinical departments devoted to nutrition, cardiovascular and renal diseases, obesity and diabetes are in close vicinity of I2MC. It helps the involvement of a large number of MD-PhD to the scientific activity of the laboratories. More than 25 clinical research protocols coming from original research obtained by I2MC teams have been performed during the last three years.

The industrial valorization of the research is another strength of I2MC. Numerous structured collaborations are ongoing with industrial partners, from SMEs to big pharmas. I2MC research directly contributed to the creation of 4 start up companies.


 

 

Latest publications

Molecular Biomarkers for Weight Control in Obese Individuals Subjected to a Multiphase Dietary Intervention (team 4)

PMID : 28482007 | Revue : J Clin Endocrinol Metab

Auteurs : Bolton J, Montastier E, Carayol J, Bonnel S, Mir L, Marques MA, Astrup A, Saris W, Iacovoni J, Vi...

Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells (team 3)

PMID : 28239646 | Revue : J. Clin. Invest. Insight.

Auteurs : Y.Y. WANG, et al.

Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice. (team 3)

PMID : 28681995 | Revue : Endocrine

Auteurs : C. BERTRAND, et al.

Job offers

  • [CDD 31 mois] Postdoctoral position in “GPCR cell surface architecture”

    (team 8)

    A 31 months post-doctoral position (ANR french funding “GRApHICS”) is available for a highly motivated post-doc fellow to join a research group specialized in the pharmacology of G Protein Coupled Receptor (GPCR) to study the cell surface organization of these receptors in living cells using AFM-single molecule force spectroscopy.
    Project summary. G protein-coupled-receptors represent the largest family of cell surface receptors and major drug targets. The existence of active GPCR oligomers, that could constitute novel targets for drug development, is still a matter of debate. AFM-single molecule force spectroscopy (SFMS) has recently been used to probe/unfold reconstituted GPCR in liposomes but such studies are still lacking in living mammalian cells mainly owing to interferences between the AFM tip and the plasma membrane. We recently succeeded to unfold GPCRs at the surface of living mammalian cells using AFM-SMFS (unpublished data) , allowing us to depict specific clusterization of these receptors. The present project aims now to extend our study in living CHO cells to: i/ understand the molecular determinants influencing their surface organization, ii/ probe ligand-receptor interactions, iii/ refine the AFM tip chemistry for native cells analysis, iv/ automate SFMS analysis, v/ deepen the statistical mathematical analysis.
    This fundamental project should have major impact for the search of future innovative drugs targeting GPCRs as it will pave the way for developing “specific oligomeric-receptor” drugs with optimized clinical benefit/risk balance.
    The Sénard/Galés team at the “Institute of cardiovascular & metabolic diseases” (I2MC) (http://www.i2mc.inserm.fr/index.php/en/), University of Toulouse III, France, provides a unique training environment for both discovery-based and translational therapeutic cardiac research combining cardiac medical doctors and researchers from both fundamental and physiological fields. Current projects in GPCR pharmacology in the team focus on investigating the molecular mechanisms underlying biased agonism, a recent concept in the field that allows alleviating II adverse effects associated with GPCR drugs.
    The candidate will be hosted at I2MC in a quite new laboratory but will work in close interaction with a biophysicist Dr Etienne Dague, CNRS, LAAS-Toulouse) specialized in the use of AFM in living cells and working with Céline Galés since several years (AFM experiments will be performed at LAAS), but also together with a chemister (Emmanuelle Trevisiol, CNRS, LAAS-Toulouse), a mathematician (Pr Jean-Marc Azais, Institut de Mathématiques, UPS Toulouse) to refine the AFM chemistry and process the AFM data.
    Requirements:
    The ideal candidate should hold a PhD or MD with a strong background with cell surface organization of transmembrane receptors and cell biology. Individuals with additional working knowledge in GPCR pharmacology and Atomic Force Microscopy (AFM) are strongly encouraged to apply. Moreover, individuals with specific experience in AFM can also apply. Excellent knowledge of English, good interpersonal and communication skills are also required.
    Please send a CV, names and contact information of three references and a short description of your scientific interests by email to Dr. Céline Galés (celine.gales@inserm.fr) and Dr Etienne Dague (edague@laas.fr )
    Gross salary: 2 544,51 € / month
    Starting: Open until filled